InsidersTradesSigma
Track the Health Catalyst, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Health Catalyst, Inc. has recorded 367 insider filings. Market capitalisation: €119.7m. The latest transaction was disclosed on 3 September 2026 (Retenue fiscale). Among the most active insiders: Llewelyn Linda. Every trade is openly available.
367
Insider Decl.
n/a
Thresholds
€6m
6 ops.
Buy Volume
€3m
80 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Health Catalyst, Inc. Hold (neutral), based on 4 analysts. Average price target: US$1.83.
37Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,760 of 29,064 companies
15.1
score / 100
Value6
Quality24
FCF yld-17%
Earn yld-149%
EV/EBITDA·
ROE-118%
Gross mgn49%
Net mgn-57%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations367 total
17,973 shares@ US$1.70360.026% mcap3.1% of flowCommon StockSEC:0001839111-26-000004:0
321 shares@ US$1.70360.0005% mcap0.4% of flowCommon StockSEC:0002086403-26-000007:0
9,766 shares0Common StockSEC:0001796545-26-000004:0
13,167 shares@ US$1.70360.019% mcap2.6% of flowCommon StockSEC:0001975281-26-000004:0
321 shares@ US$1.70360.0005% mcap0.9% of flowCommonSEC144:0001628280-26-059933
80,691 shares0Common StockSEC:0001320490-26-000003:0
80,691 shares0Common StockSEC:0002046471-26-000001:0
80,691 shares0Common StockSEC:0001397180-26-000001:0
80,691 shares0Common StockSEC:0001796545-26-000003:0
34,485 sharesCommon StockSEC:0002086403-26-000006:0
34,485 shares@ US$1.69180.046% mcap100.0% of flowCommonSEC144:0001628280-26-042293
336 shares@ US$1.37020.0005% mcap100.0% of flowCommon StockSEC:0002086403-26-000005:0
18,804 shares@ US$1.37020.025% mcap2.6% of flowCommon StockSEC:0001839111-26-000003:0
1,124 shares0Common StockSEC:0002086403-26-000004:0
310 shares@ US$1.3450.0003% mcap47.3% of flowCommon StockSEC:0002086403-26-000004:1
70,455 shares@ US$1.848193.5% of flowCommon StockSEC:0002086403-26-000003:0
8,361 shares0Common StockSEC:0001796545-26-000001:0
4,966 shares@ US$1.65995.8% of flowCommon StockSEC:0002086403-26-000002:0
20,838 shares@ US$1.65994.0% of flowCommon StockSEC:0001975281-26-000002:0
26,970 shares@ US$1.65994.7% of flowCommon StockSEC:0001839111-26-000002:0
13,836 shares@ US$1.65991.7% of flowCommon StockSEC:0001780878-26-000002:0
930,000 shares0Common StockSEC:0002086403-26-000001:0
289,000 shares0Common StockSEC:0001975281-26-000001:0
507,500 shares0Common StockSEC:0001839111-26-000001:0
191,500 shares0Common StockSEC:0001780878-26-000001:0
25 of 367 declarations
关于 Health Catalyst, Inc.
Health Catalyst, Inc. (股票代码：HCAT) 是一家总部位于美国的医疗保健数据和分析公司，在美国纳斯达克上市。该公司由医疗保健分析行业的先驱于 2008 年创立，总部位于犹他州盐湖城。其核心使命是帮助医疗保健组织将分散的临床、财务和运营数据转化为可衡量的改进。随着时间的推移，Health Catalyst 已从纯粹的分析供应商发展成为更广泛的医疗保健智能平台提供商，结合了软件、基于云的数据基础设施和专业服务。([sec.gov](https://www.sec.gov/Archives/edgar/data/1636422/000163642226000035/hcat-20251231.htm?utm_source=openai)) 该公司的业务线围绕一个基于云的数据平台以及一套专为医院、卫生系统和其他护理组织设计的应用程序和服务。Health Catalyst 使客户能够摄取、规范、管理和分析医疗保健数据，然后应用这些洞察力来提高护理质量、降低成本、增加收入并管理人口健康。其产品包括数据平台功能、分析和绩效改进应用程序、患者参与解决方案以及实施/咨询服务。这种组合为公司带来了经常性软件收入以及服务主导的客户关系。([healthcatalyst.com](https://www.healthcatalyst.com/who-we-are?utm_source=openai)) 从竞争角度来看，Health Catalyst 定位为利基专家，而非横向企业软件供应商。其差异化在于深厚的医疗保健领域专业知识、悠久的运营历史以及与经验证的财务和临床结果相关的数千个改进项目的记录。管理层将该业务描述为一家医疗保健智能公司，这种定位反映了其试图在特定行业工作流程、结果和安全性方面进行竞争，而不仅仅是通用商业智能功能。实际上，这使得 Health Catalyst 与其他医疗保健数据和工作流程参与者并驾齐驱，而其领域深度可以成为一个重要的进入壁垒。([healthcatalyst.com](https://www.healthcatalyst.com/who-we-are?utm_source=openai)) 主要产品和战略举措包括 Health Catalyst Ignite 平台、患者参与资产（如 Twistle）以及与 Lumeon 和 Upfront 相关的产品。2025 年，该公司还在 Databricks Marketplace 上推出了十个 AI 集成数据工具包，突显了对 AI 驱动、模块化和云原生用例的更明确重视。安全性和合规性仍然是医疗保健领域重要的商业差异化因素；Health Catalyst 于 2025 年末宣布其多项产品获得 HITRUST r2 认证，巩固了其企业级定位。([healthcatalyst.com](https://www.healthcatalyst.com/news/unitypoint-health-to-unlock-next-phase-of-analytics-innovation-by-activating-health-catalyst-ignite-tm?utm_source=openai)) 从地理上看，该业务主要以美国为中心，服务于美国医疗保健组织及相关网络。2025 年最新的公司亮点显示，商业化和产品开发持续进行，包括 Catalyst Awards 计划以及新的客户/合作伙伴活动。2026 年 3 月，Health Catalyst 报告 2025 财年收入为 $311.1 million，调整后 EBITDA 为 $41.4 million。该公司还在 2026 年进行了治理和领导层变动，包括任命 Ben Albert 为首席执行官以及 2026 年 4 月的董事会层面变动，投资者可能会将其视为持续战略调整和执行重点的一部分。([ir.healthcatalyst.com](https://ir.healthcatalyst.com/news-releases/news-release-details/health-catalyst-announces-winners-2025-catalyst-awards?utm_source=openai))
